EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

September 13, 2022

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 61 min

Earnings Call Speaker Segments

Operator

operator
#1

Good afternoon—or good morning, depending on where you're joining from—and welcome to El.En.'s Half Year 2022 Financial Results Conference Call. This call is being recorded today. <<operator_script>> Joining me are Andrea Cangioli, El.En.'s Managing Director, and Enrico Romagnoli, El.En.'s Chief Financial Officer and Investor Relations. Before we start, I'd like to note that management will make remarks on this conference call regarding future expectations, plans and prospects, as well as forward-looking statements. Some of the statements on this call—including those dealing with the company's beliefs, plans, objectives, estimates or expectations about possible future results or events—are forward-looking statements. Such statements carry known or unknown risks, among them general economic and business conditions and the conditions of the industry in which we operate, and they may be affected if our assumptions prove inaccurate. As a result, no forward-looking statement can be guaranteed, and actual future results, performance or achievements could differ materially from what those forward-looking statements express or imply. The company assumes no obligation regarding the content, nor to update the forward-looking statements to reflect events or circumstances arising after the date hereof. At this point, I'd like to hand the call over to Mr. Andrea Cangioli. Please go ahead, Andrea.

Andrea Cangioli

executive
#2

Thanks once more, Janica. Good morning, everyone. We appreciate your joining us on this call, which follows the publication of our financial report covering the first 6 months of 2022. With me here are Andrea Cangioli, Management Director of El.En., and Enrico Romagnoli, our CFO and Investor Relations Manager for El.En. The results for the 6 months were excellent once again, and naturally we're extremely happy about that. Revenues climbed 19.4%, far exceeding the 10% minimum growth we had projected for the entire year, and profits are rising strongly too — not merely in absolute terms through the macro effect of volume growth, but in margin on revenue as well. With EBIT margin reaching 12.7% in the 6 months, we are approaching profitability levels the group has not experienced in a long time, and they surpass our initial expectations too. To give you a full picture of where we stand right now, I'd like to turn to the specific market environment in which we operate and the positioning of our operational structure/environment. We're speaking of a very healthy and promising environment across most of the market segments and sectors where we compete with our health and system solutions, which can both fulfill and simulate the needs and desires of our customers and potential customers.

Andrea Cangioli

executive
#3

Let me touch on our 3 biggest application markets: medical settings, medical surgery, and manufacturing. Those 2 medical segments follow the broad pattern of joining our long-term favorable cycle, which social and demographic trends are driving. People want to look and feel better, and they're willing to pay for it. Even as the population ages on average, folks still want to keep a more useful appearance, and when age makes specific surgery necessary, patients want those procedures available right now with no downtime and with higher pay. Our technological offerings aim first of all at detecting disease, but our innovation also targets making new durable, effective, and affordable procedures available so as to grow what potential customers want. And at the same time, to grow the market for our devices. The manufacturing work neither has nor expects a growth trend as strong as the one expected for our medical segment. Yet it does carry the general need to boost cost and quality effectiveness across each process, and it is eager to put money into solutions that make such improvement possible. Our technology for the manufacturing board lets production processes be materially enhanced from several points of view: cost effectiveness, productivity, volume, and last but not least, environmental impact.

Andrea Cangioli

executive
#4

To put it plainly, a positive overall direction is what our key markets are showing at present, and that direction is being reinforced by the combined creative efforts behind our offering, which drive demand through ongoing gains in system performance and by tying into the ROI our customers receive. If we accomplish a great deal at the level of our particular market relative to the broad economic direction, circumstances shift rather substantially, because what we confront is among the harshest and least predictable situations seen over the last year. During May 2020 and 2021, the rebound that followed the pandemic proved powerful and let the global economy climb out of the prolonged slump. We managed that with such force that it produced an inflationary path. The war breaking out in Ukraine has brought to the European nations added uncertainty and <<inaudible>> of a war that is very near, together with the unwanted side effects of losing the means of the pension in relation to a market holding great promise. And above all, importing an extremely difficult energy cost setup, which pushes inflation further and, second, brings a major shift for a number of energy venture businesses and for half of the financial balance. Energy-intensive is not what our business is. A very large energy component affecting our cost of goods sold is not something we have, yet we do carry higher expense stemming from energy costs.

Andrea Cangioli

executive
#5

Meanwhile, the U.S. economy has lately been experiencing inflation and a recession at levels we haven't seen in recent memory. China's economy has still not emerged from its prolonged downturn, and added lockdowns are slowing things further in an economic climate that had actually been providing a boost toward better results. So the macroeconomic trends aren't favorable, yet aside from the Chinese uncertainties—which held back our sales growth during the month—they produce no negative growth for our business. Still, the overall picture is well understood. To lay out the biggest challenges we've faced across these 6 months, we really need to zoom back in on our business and on particular activities within the new business operations. I'm referring to buying the materials and components required for our production processes. Beyond price inflation—which is a cost matter and can be handled to some degree—the genuine problem remains the unavailability of certain components. Lead times have stretched well beyond 50 weeks, and delivery terms have grown unreliable as a result before pushing several components. I could talk for an hour about delayed shipments of safe components, what suppliers call allocation of deliveries, interruptions to delivery, and naturally the monstrous costs in the region.

Andrea Cangioli

executive
#6

Since we couldn't guarantee a steady supply of material that meets our shaping standards and keep our vendors on a consistent curve, we chose to speed up purchase volumes and feasibility deliveries to us, and to raise the quantity of material we now hold. The group's physical production cycle is now significantly longer than in the prior quarter, because we attempted to get ahead of delays and cancellations — to avoid the delays and cancellations that have been appearing over the last year, which could otherwise fully halt certain production lines. On top of that, by paying advances to the banker to gain priority in supply, and by paying suppliers sooner than we used to, we also further strengthened the working capital financial cycle. That shows quite clearly in the cash usage we had in the 6 months and in how our net financial position projections moved during the period. We invested some of the cash on hand, and in most cases we managed to stabilize production volumes, as our order profit and loss performance reflects. Only in a few circumstances did the organizational and financial efforts have to give way to material shortages and slower production grades, mainly during the <<inaudible>> of the summer at our production line in our factory in <<inaudible>>.

Andrea Cangioli

executive
#7

Our approach to this path has been very restrained, and that turned out to be crucial in letting us keep production volumes up and even grow them. Part of the financial interest should be viewed as temporary, tied to the supply chain emergency, and part stems from the ongoing and anticipated growth of production volume. On top of that, certain factors make the financial cycle seasonally stronger toward year-end. As in the other year, we anticipate that part of the working capital expansion will be up. And we've -- we sought to give you the specifics on the different elements of our 6-month cash observation. A cash reset point concerning the use of cash -- during the period, I'd like to return to the subject of how we generated earnings in this 2022 today and how we managed to lift EBIT and EBIT margin to the record level we are presenting. Sales volume was the first driver; 19.4% average gross was an exceptional achievement. And medical sales -- sales in the medical sector -- rose close to 25%, which permits solid leverage of operational expense. Sales growth was weaker in the industrial sector, only 13.2% as I said, yet still an outstanding performance, given that a slow performance hit us, caused mainly by the Chinese lockdown, which slowed our manufacturing and our sales activities in China.

Andrea Cangioli

executive
#8

Sales gross margin came in 0.8% better during the period. I'd like to walk through 3 things behind that. To start, the medical segment grew more quickly, and that business delivers an average sales margin of roughly 45% across 6 months, which supports a mix percentage. Next, a sales mix that was more favorable inside the industrial segment added to the margin gain as well. Better marginality in China more than offset the margin decline in European sales, which came from a plan to grab market share fast across the European territory. Medical segment margins stayed more or less flat, helped by higher sales into the U.S. and by the stronger U.S. dollar — a benefit that offset the modest margin dip caused by cost inflation and by an overall rise in sales to large volume customers who also carry volume prices. Being able to lift margin as sales grew was the key factor in EBIT margin expansion, along with solid operational expense cost. Research and development work paid off during the period, as did our regulatory efforts which, as you know, in medical sales permit selling in particular countries, occasionally here or months following the product's first release.

Andrea Cangioli

executive
#9

To give you an example, today we reached an agreement concerning the <<inaudible>> in laser beam for health laser emission in Taiwan and Korea. Among the new products, I want to highlight the growing clinical evidence and market access that has been accepted thanks to the clinical proof of efficacy for more — and the major CO2 devices, which incorporate a take of 15 40-nanometer wavelength laser store, letting thermal effects drive the traditional ability CO2 effect in terms of it. A new deal such as a CO2 device built for the U.S. market is set to be released to sales in early 2023. Among others, we are further challenging our wide product range of lateral thermal systems by enhancing the performance and usability of our data module range, while the system is expected to release the new powerful system for trading in early 2023. And the body shaping product range is also being enhanced with improvements to our flagship on that pool. Sheet metal laser carton systems are being equipped with laser sources of increasing power, but most importantly, on the application side, the effectiveness of laser cut with 20 kilowatt and 30 kilowatt laser sources is continually built by our application special, enabling unprecedented customer achievement, as some of you could appreciate, like during the recent Open Day we held in Florence and <<inaudible>>.

Andrea Cangioli

executive
#10

Before Enrico walks everyone through the details of our financial results, I want to bring up the celebration we held a few days ago — a party at that fantastic venue in Florence, where both the present and the future Florence paid tribute to the scientists who laid the technological foundation of our business, and among them was Professor Gérard Mourou, the 2018 Physics Novelist. That gathering of time, business and our people — there are German that promoted that night — is one of the key success factors in the El.En. history. We signed an R&D effort playing a crucial role in the product innovation sources that is central for business development. Enrico, please go ahead.

Enrico Romagnoli

executive
#11

Thank you. Thank you, Andrea. And as Andrea already mentioned, during the first six months of this year, El.En. posted additional record results, with consolidated revenues of EUR 327 million, which is up 19% versus last year, and once again, another double-digit rise in both of our sectors, the medical one and the industrial one. Alongside the sales growth, profitability also improved, with an EBIT of EUR 41 million, an increase of 34% when comparing the figures from the first half of last year. Thanks to the high sales volume, we saw a sharp rise in EBIT and in the EBIT margin, with an impact on sales of 12.7%, higher than last year's 11.3%, and higher than the previous quarter. And thanks — and higher than the first quarter's 11.8%. And in Q2, the EBIT margin of El.En. Group stood at 13.3%. The sales increase also comes together with an improvement in gross margin, and the drivers behind that improvement were already explained by Andrea. And thanks to the gross margin improvement and the stability of the impact on sales of fixed costs such as operating expenses and staff costs, EBITDA was positive at EUR 47.2 million, a rise of 20.7% compared with the EUR 39.1 million last year.

Enrico Romagnoli

executive
#12

Turning to turnover, it stayed completely flat at 14.4% this year versus 14.3% last year. EBIT market came in at a positive EUR 41.4 million, up 34.1% from EUR 30.9 million a year earlier. Market upsale reached 12.7%, a record level and significantly better than last year's result. A positive contribution came from the reduction in accrual for risk and charges versus last year, when the increase was mainly tied to the warranty, reflecting higher sales volume and some extension of the warranty period. Pretax income posted a positive balance of EUR 41.6 million, a 30.8% increase, and net income for the group was EUR 28.4 million, up 26.6% after a 26% tax rate. On the balance sheet, net capital employed rose 50% owing to the reduction of net financial position. The group's net financial position stayed positive at EUR 43.9 million and fell by EUR 72 million in the period, compared with EUR 115.8 million at the start of the year and EUR 85.8 million at the close of Q1 2022.

Enrico Romagnoli

executive
#13

Looking at the cash flow chart, you'll notice the fresh decrease in cash flow caused by the rise in net working capital, assuming EUR 46 million to back the fast expansion and to handle how stock exchange prices are affecting the business. The movement in other current payables and receivables came largely from EUR 14 million tied to lower advance receipts from customers—particularly in China, where earlier acquisition plus sales volume, which we saw in the semester, accounts for EUR 7 million—rising at a quicker pace to supply what's needed to guarantee family supplies, along with another EUR 7 million reflecting a temporary negative swing in tax payable and receivable for income taxes and GST. Dividends of EUR 17.2 million were also paid during the reported period, EUR 16 million of that being equal to EUR 0.20 per share, while investment in new building plants and our fixed assets cut cash by EUR 9.6 million. Now, EUR 3 million of liquidities went into our insurance policy and appear under financial fixed assets to reflect a multiyear measure. Investments of this kind were already booked in earlier financials of the group; being mid- to long-term in nature, they sit among noncurrent financial assets and therefore aren't included in the financial position.

Enrico Romagnoli

executive
#14

At June 30, the total worth of this type of instrument stood at EUR 21 million of units. Turning to business by sector, the medical sector posted 25% growth versus the same period a year earlier, with strong growth across all application segments. Aesthetics, the most important sector, accounting for a 60.7% share of total medical turnover, shows revenue of EUR 111 million against EUR 94.1 million in the same period last year. The Aesthetics share slipped slightly over the 6 months because of very rapid growth in the other segment, mainly Surgery, up 43%, and Physiotherapy, up 25%, which surpass the results achieved before the COVID pandemic. Sales in after safe service came to close to 20% of the sectors turnover, with sales of EUR 53.3 million, a strong increase of 35%. Thanks above all, with the sale of optical fibers for subject application in neurology, with production having suffered a sharp go down at the beginning of 2021 due to the technical production problems overcome the following months. In the medical sector, there are brilliant trends, both from the point of view of turnover and profitability in part of system <<inaudible>> and the safe ability of components has lowered the production and growth of late and consequently over so.

Enrico Romagnoli

executive
#15

The Japanese branches are still dealing with negative fees, largely because of a weaker fee cycle on more home-use devices over the last 2 years. Turnover in the industrial sector rose 13% versus the same period a year earlier, and revenue growth confirmed the positive trend seen in recent years. That growth comes from sheet metal cutting, which was up 15% with turnover of EUR 122 million, and the sales performance in Italy was brilliant on the chilling and external side, with 52% growth over the 6 months. Results for our Chinese business in the half year were hit hard by COVID issues and the lockdowns that followed. Turnover there fell 16% in local currency, and net income dropped 25%. In euro terms, the sales amount was reduced by 3% and net income by 15%, thanks to the renminbi strengthening against the euro. The market segment stayed essentially stable at over EUR 10.8 million and offers further good development prospects. Meanwhile, the sales sector grew 8% with EUR 2 million in revenue, and aftersales service was up 9%. Finally, from a geographical standpoint, revenue growth in the first 6 months of 2022 was rather significant across various areas of the world.

Enrico Romagnoli

executive
#16

Turning to Italy, the biggest overall sales gain is there — up 31%, averaging a 7% rise in medical and 43% in industrial. The group's growth rate in that country was matched by Europe at 28%, with medical there up 29% and industrial 25%, similar rates. For the rest of the world, the first half of 2022 came in at a 15% increase on average, driven by strong medical growth and a very good showing in the U.S. market, whereas industrial slipped 1% because of China. Andrea, over to you for the guidance.

Andrea Cangioli

executive
#17

Enrico, as I said earlier, we're seeing something very strong and optimistic. We're examining our capabilities along with all the market potential over the long term, but over the short term as well. On the negative side, external recurring challenges — the models have diverged from the excellent growth reps we're facing. The stronger that growth has been, an <<inaudible>> for us is the persisting tendency of COVID-19 on the Chinese territorial and economy. Finally, regarding the guidance. The starting point here was the previous change of more than 10% revenue growth on 2021 and EBIT growth on 2021, which we released in March and then subsequently in May. To be precise, it was more than 10% in terms of revenue, while no indication was given about EBIT margin. The 6-month financial results assets are widely compliant with the lead guidance by margin 9.64% and revenue increase and a needed increase, moreover very 12.7% record EBIT margin level. In the second half, we'd like to continue to grow 5 times exceeding the EUR 660 million revenue threshold, which would mean 30% revenue growth in H2, again, against H2 2021 and 16% overall yearly revenue growth. We expect EBIT — I mean this would be a minimum level. We expect EBIT to grow with revenue.

Andrea Cangioli

executive
#18

We're demonstrating an EBIT margin improvement of over EUR 1 billion. Our costs could be hit by inflation to a greater degree than we can recover through the price increases we're implementing. Operating expense tied to energy is set to rise materially, particularly from the Italian compound. And a third factor connects as well to the revenue growth guidance — which is a bottom — which is the quarter — sorry, the guidance is central to our capacity to sell, to grow sales volume in China and then to capture the leverage effects that are significant in the turning basic margin results, sorry, what I meant is that at this moment we have very high visibility on revenue development in China owing to the unstable situation there. If we could grow our volume in China beyond the effect in the revenue projection that we are to share, we would also be able to achieve a better leverage effect on our P&L. H1 did not take into account a good performance in the Chinese market. We are counting on improvement in the second half, but we must be able to operate under more normal order conditions, without the continued interaction caused by lockdown.

Andrea Cangioli

executive
#19

That brings our presentation to a close. And at this point, I think we're ready to take your questions.

Operator

operator
#20

<<operator_script>> Andrea, we’ve got — we have two questions. The first one is from François Robillard at Intermonte.

François Robillard

analyst
#21

All right, I have 3. The first concerns working capital. You invested fairly heavily across the second quarter and the first half. I'd just like to understand how many of the factors you cited will, in your view, stay structural? You referenced somewhat higher inventories as well as the pattern in advance payments, both to 2 suppliers and received from clients, particularly in China. So I suppose my question is about the cost structure behind those trend changes? And might we see a reversal during the second half of the year? Or would a reversal more probably come in 2023? That was my first question. I have a couple more after this.

Enrico Romagnoli

executive
#22

Alright. So the working capital trend has several components to it. The key elements of working capital — I'm talking about inventory, accounts receivable, and payroll accounts — should see their balances come down, and their effect on sales should shrink by year-end. As for how advances received from customers and advances paid to vendors move, that depends entirely on order bookings and on what kind of order bookings they are. If we can land a sizable order booking, particularly in China, like the one we had at the end of 2021, this allowance would grow further. For that amount to rise in a positive way, we need an order booking bigger than the one we have today. That said, even given the contract situation, we don't anticipate the advances balance will work, and it will be cash decretive as we move toward the end of the year. So broadly speaking, we expect total net working capital's impact on sales to come down by a few percentage points between now and the end of the year.

François Robillard

analyst
#23

My next question concerns how much visibility you currently have into demand strength across our 2 product categories. Could you share your expectations for demand in the medical segment and the industrial segment for the second half, and also give us a brief comment on your order backlog at present?

Andrea Cangioli

executive
#24

Looking at demand, it has remained robust across every segment, even with the broader economic conditions being considerably tougher. Our sole genuine issue is delivering on time and raising output levels. That is why our backlogs remain very substantial, although at most of our companies they are slightly lower than they were at the start of 2022. In just 1 instance is our backlog materially above where it stood at the beginning of the year. That instance involves a company which, as I noted during my presentation, has been affected by the component shortage more than every other company in the group, and it was unable to raise its volume and therefore could not gauge its demand, which is still moving at a very high level in order backlog. So we have a lot of confidence about the near future, given how consistent our order backlog is. The same holds true for the order backlog in manufacturing, in both the laser market and castings, as far as our European and Brazilian facilities are concerned. The single area where our order backlog is less full than we would like is China, where, as I said earlier, demand is under threat from the ongoing pandemic hanging over daily life and business activity on Chinese territory.

François Robillard

analyst
#25

And just one final question, if I may, regarding your EBIT guidance. You've given us more detail on the second-half trend. Strictly speaking, when you look at what your guidance covers, the range for the second half is quite wide — between EUR 25 million and EUR 42 million for EBIT in absolute terms, or 7% to 12.7% when it comes to margins. Where within this guided range do you see yourselves landing, or do you expect to arrive more at the higher end or the lower end?

Andrea Cangioli

executive
#26

Naturally, the guidance is what it is. They can’t get overly precise, because to put it another way, we had been given a different guidance — but when we set a minimum expected sales volume of EUR 660 million, we also acknowledge jointly that if conditions in the medical segment stay as they are and China improves only slightly, we would be in a position to exceed that figure. The same holds true for the EBIT margin. So if we manage to grow volumes in the Chinese market the way we expect to across all the other markets, the leverage effect could offset a modest margin correction that we anticipate in the second half stemming from inflation. So we aren’t discussing — talking about big swings, but we are discussing, we anticipate an EBIT margin only slightly under the EBIT margin, the record EBIT margin relative to — of the first half unless and expected to be, which is why the load factors are incorporated in the guidance. Sales growth would permit leverage on operating expense.

Operator

operator
#27

Andrea — Andrea Bonfa from Banca Akros, you have the floor now.

Andrea Bonfà

analyst
#28

Some of what I asked has already been covered. Andrea, could you go deeper on the point you raised in your presentation—that China profitability helped or offset things—given that we're seeing some aggressive pricing in the Italian laser cutting business, the metal laser cutting business? And specifically, the performance, and more, of the Italian market in metal laser cutting was impressive. Is it fair to expect that to continue? What's your potential market size in that segment? Could you replicate that across Europe, and if you can expand on that a bit. And if you could recap once more, perhaps a little more slowly, the new products you mentioned earlier, which are set to be launched in 2023.

Andrea Cangioli

executive
#29

Thanks, Andrea. So yes, I was referring to the following: we had an extremely strong 6 months for sales from Cutlite Penta, the Italian facilities for laser cutting, where sales rose by more than 50%. So there was an exceptional sales volume in terms of sales. This sales volume was of sales, also at the expense of a margin reduction, which in part is a strategic story. In part it is also due to the fact that we took orders classified a long time ago, and we are ramping up production in order to reduce delivery returns. But some of the delivery returns were so long that purchasing took place with higher costs than we had, let's say, planned at the moment of taking the order. For this reason, we are extremely pleased with the increase of sales, but we know we have room for improvement in the margin of sales, and we could already put revenues in place in order to keep these tie margins higher in the second half of the year. The other thing happened in China, where there was a decrease in sales comparing 2022 first half sales to 2021 first half sales. A decrease in sales in the local currency, and that, of course, we then translated to Europe for our consolidated reporting factor has been strengthening on the renminbi and reduces the impact in production.

Andrea Cangioli

executive
#30

However, during this period, the mix of what we sold leaned more toward high-power systems, which we sell into market segments carrying better margins—such as the segment we're moving toward—and the margin on sales in China got better, replacing the <<inaudible>> margin. So, taking the industrial sector's sales margin as a whole, we see a modest gain, and that had a favorable effect on the consolidated gross margin balance. As for what our markets can do, we'll stay very optimistic, given what this growing-power laser cutting system actually lets you achieve, how we've handled those systems, and how we've become recognized as the true leaders in that segment. The distance separating us from the biggest competitors remains substantial—for example, the market leader <<inaudible>>, when it reports 6 months sales, I mean, is posting a slight sales increase, and I believe they come in under EUR 500 million for 6 months revenue. Our division—our sheet metal cap division—I don't recall, perhaps Enrico could tell me, what the division's actual sales revenue is, and not merely the division's customer system.

Enrico Romagnoli

executive
#31

Moving to the second item, dividends. Let me see if I can locate that — hold on a moment while I pull up the figure. Right now I can't recall it from memory, given the royalty situation. In any case, there'd be no need for you to produce one yourself. On the third question, I listed several products that are set to lead our new offerings. The first is a new dual-wavelength system, a CO2 laser platform, with deliveries to the U.S. market beginning in 2023. Beyond that, we have fresh versions of existing products. As you're aware, <<inaudible>> represents our biggest segment, and we address it with a number of high-level products. Data is driven by the model family, the organic family, the Founder system, and the vehicle system. I was referring to enhancements in motor spending through renewed systems, mostly ASV, which additionally brings new handsets that widen what the motor platform can do — not solely confined to removal capabilities, but also featuring new specialty handsets and allowing the motor laser systems to serve as a platform for vascular treatment and the <<inaudible>> as well. I think I also noted — and I'm about to get to it — the clearance we secured for Red Pasteur, a dermatologic system employed to stimulate collagen, essentially an anti-aging system that is particularly effective in the enhanced area.

Enrico Romagnoli

executive
#32

So we secured approval in Korea and Taiwan—both really important markets for this product. They aren't our only market, but the timing just happened to line up that way, since R&D work is essential when it comes to technically delivering new products. That's why the R&D regulatory effort sometimes sits here for months following the product's technical release, which permits selling it in chosen countries and makes it available for the research.

Operator

operator
#33

And next, we have a question from Luis Cazalot at Good Value for Money.

Executive

executive
#34

One quick thing about income taxes — I may be mistaken, but it seems like the tax figure came in much higher relative to EBIT. Is there some particular reason for that, or — I only glanced at the slide, but my read is that you went from EUR 7 million to EUR 11 million, an increase of EUR 4 million; perhaps I'm wrong. Yes, right here.

Enrico Romagnoli

executive
#35

Our tax rate has gone up versus a year ago. Last year it was roughly 22%, and at this point we're at about 26%. The key driver is that net income — the pretax income of the Chinese company — shifted some product toward the additional pretax income. Also, China's tax rate is below Europe's. In Europe it's roughly 25%, 30%, while in China it's roughly 15%. That's the primary explanation for the higher tax rate.

Andrea Cangioli

executive
#36

Alright, I’ll take that question from Andrea Bonfa, along with the figure. For that indication, revenue during the first half of 2022 came to EUR 126 million, and measured against electronic it represents roughly 1/3 right now — actually a bit under 1/3, somewhere around 1/3. Three years back, we stood at 1/10 of electronic, perhaps even less. So market share is moving in our favor. We see room to keep growing our activity across Europe. Our exhibition calendar is quite full for the second half of 2022, and that includes being physically present at the last sale of Hannover — the key shipment event that took place there. We will also be presenting at the past in Chicago, where we hope to begin planting a seed for expansion into the U.S. market — a very significant market, one where our sheet metal system could see solid potential expansion.

Operator

operator
#37

And at this point, we'll take 3 questions from Giovanni Selvetti at Berenberg.

Giovanni Selvetti

analyst
#38

Are you able to hear me?

Andrea Cangioli

executive
#39

Correct.

Giovanni Selvetti

analyst
#40

I have a few questions. First, could you break down how much of the rise in profitability and the gross margin level came from the exchange rate effect—especially the U.S. dollar—and how much stemmed from the different mix between medical and industrial? Second, regarding Quanta: if you look at that single company, it is growing at an amazing pace, more than 50%, much more than the other companies in the group in the Medical segment. What is driving this amazing performance? Is it due to the rebound of the surgical business, or what is it? Third, quickly on CapEx: during the results call in mode, I stated that they opened a new subsidiary in Italy, which is already positive and contributing to the positive results of the European group, but do you see an increase in competition in the domestic market? And if yes, how is the company planning to tackle it? And the last one, again on Aesthetics: listening to the American piece, there seems to be demand that is stronger than ever and seeing decline also accepting higher cost of the leasing.

Giovanni Selvetti

analyst
#41

Do you see that happening for you down the road?

Andrea Cangioli

executive
#42

Sorry about that — would you mind restating the first question? I didn’t catch what the client said about the higher cost of the leasing.

Giovanni Selvetti

analyst
#43

Laser system purchase costs have risen as of now. Yet, judging by what your peers report, demand is so robust that the decline will take on the pricier machine acquisition since the land is steel strong. Do you see that happening for you?

Andrea Cangioli

executive
#44

All right, so that's four questions. The impact from exchange rates was significant, though we didn't disclose the amount — we're more focused on the percentage of the impact. For exchange rates, I don't believe the P&L effect on gross margin would be more than a percentage point over perhaps 6 months, pointing to financial. That's why I said the increase comes mainly from mix. The mix is what we made heavier. So that accounts for roughly half of the margin change. The other half is from margin improvement in the industrial sector. The foreign exchange effect isn't an active effect in an excess of margin reduction — more or less the same, of the signal. Why did the Quantum growth effect get compared from all the others?

Giovanni Selvetti

analyst
#45

Quanta.

Andrea Cangioli

executive
#46

What's the reason behind Quanta? Yes, there's a technical explanation for this. Quanta performed strongly and made solid sales gains in the third segment, plus they were carrying momentum into the first half of 2021, when they ran into 2 structural issues. First, we began and wrapped it up. A production issue arose in the optical fiber supply. We had to halt shipments of optical fibers, which make up a meaningful share of revenues, because of a problem that came up at one of our suppliers. Basically, this was a seriously troubled product situation — the supplier wasn't in compliance as far as we could see, and we were forced to shut the factory down under very strict regulatory requirements, and we couldn't switch to another manufacturer. The bottom line is we had to wait, and we had to requalify another supplier from a medical standpoint, and that produced a revenue delay in optical fiber during the first month of 2021. The second event, which created some trouble — not big, but some issues — that weren't there in 2022 was the ERP system change at Quanta System, with SAP going live on January 1, 2021. And as you know, at companies like Quanta System, switching the ERP system can, in some way, even though we invested a lot of money in sales and, let's say, in the trade staff, actually have an impact during the first month of production back in 2021.

Andrea Cangioli

executive
#47

When it comes to this region, the comparison works out especially well for us. We don't anticipate Quanta being able to keep up that sort of growth rate through the second half of the year. InMode is the most brilliant of our competitors, even though what they often compete with is weapons, and those are entirely different from ours. What they sell are low technology products backed by an excellent marketing package and support, and they earn exceptionally high margins. Our average prices are exceptionally high as well. We know they have a presence in Italy, and we know that they could become a strain on our market position there. Yes, we need to be closed for sales mode, because a customer buying from InMode isn't necessarily a customer that we own. There's a high possibility that our customer buying from InMode is not a customer who would buy from us. But it's early for me to give you a comprehensive answer on this specific topic and on the current trajectory. Looking worldwide, it is evident that InMode is doing very well. It is evident that we are doing very well at the same time. And so, since I believe we are not looking for the same kind of customer, I believe that also in Italy, where we were present, it is not necessarily going to carve away our dominant position.

Andrea Cangioli

executive
#48

And then your final question concerned leasing costs, of course—with interest rates going up, you inevitably end up bearing a higher cost. Also, when we implement price increases, since we are raising prices for our customers, they will likewise face a higher purchase cost, in addition to the financing expense. Speaking today in the middle of September, we are not seeing any material impact on demand stemming from this increased purchase cost for the medical doctor. I don't know—perhaps 2 months from now things could look different. But for the time being, the trend remains strong.

Operator

operator
#49

Andrea, our list of questions has now run out. Is there anyone else from the floor who wants to ask something? No. So, if nothing further has come in, we'll wrap up this call. Thanks for joining this conference, and we look forward to having every one of you with us next time. Good afternoon, everyone.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.